Get to know our clinical trials
Trial to evaluate the efficacy, safety, tolerability and consistency of effect of atogepant for the acute treatment of migraine (ECLIPSE).
THE PURPOSES OF THE STUDY ARE TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF A SINGLE DOSE OF ATOGEPANT COMPARED TO PLACEBO FOR THE ACUTE TREATMENT OF A SINGLE MIGRAINE ATTACK, AND TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF ATOGEPANT FOR THE ACUTE TREATMENT OF MULTIPLE MIGRAINE ATTACKS.
Technical Summary
- RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE SEIZURE STUDY WITH AN OPEN-LABEL EXTENSION TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY AND CONSISTENCY OF EFFECT OF ATOGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE (ECLIPSE).
- Code EudraCT: 2023-506029-12-00
- Protocol number: M24-305
- Promoter: Abbvie Spain SLU
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.